@kavi_deniz: We’re proud to share that @TamarindBio has been selected to build, host, and operate the inference infrastructure layer…

X AI KOLs Following News

Summary

TamarindBio has been selected to build, host, and operate the inference infrastructure layer for TuneLab 2.0, Eli Lilly's collaborative AI/ML drug discovery platform.

We’re proud to share that @TamarindBio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models trained on over $1B worth of Lilly proprietary data to the biotech ecosystem. Tamarind will power TuneLab’s scalable drug discovery workflows and model inference.
Original Article
View Cached Full Text

Cached at: 06/11/26, 09:42 PM

We’re proud to share that @TamarindBio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models trained on over $1B worth of Lilly proprietary data to the biotech ecosystem.

Tamarind will power TuneLab’s scalable drug discovery workflows and model inference.

Similar Articles

Accelerating discovery of liver disease mechanisms

Google DeepMind Blog

DeepMind's Co-Scientist AI system helped researchers at the University of Edinburgh generate a novel, experimentally verified hypothesis linking the NLRP3 inflammasome to the mechanism of drug resmetirom in MASH liver disease, potentially enabling targeted combination therapies.